21. December 2013 · Comments Off · Categories: Doctor Research

Brigham Logo SmThe annual GIST and Sarcoma Cancer Research Conference, organized by the GIST Cancer Research Fund, serves as an invaluable forum for patients and their families to hear about the latest advances in the field from scientists and clinicians at Brigham and Women’s Hospital (BWH) and Dana-Farber Cancer Institute (DFCI).

Last year’s event, which was held in April, was no exception. More than a dozen investigators, physicians, and caregivers at the leading edge of research and care from both BWH and DFCI gathered at the conference to share the latest findings, clinical trial updates, and therapeutic advances with patients, which provide them with the knowledge they need to make informed decisions about their own treatment strategies. Below is a brief synopsis of just a few of the many research highlights from the day’s presentations.

 

More »

19. October 2013 · Comments Off · Categories: Uncategorized

22. May 2013 · Comments Off · Categories: Doctor Research · Tags:

Memorial Sloan-Kettering Cancer Center (MSKCC) is preparing for what it calls “a breakthrough clinical trial” that will test a new drug that uses a MEK inhibitor to target ETV1 in combination with imatinib on a small group of newly diagnosed GIST patients with advanced disease.

We hope to begin recruitment in August, said Dr. William Tap, Section Chief of Sarcoma Oncology at MSKCC. The Phase II trial will be small, with only about 45 participants, and will only have one site at MSKCC in New York City, he said. That’s because “we just want to show that this approach works,” before recruiting for a larger scale trial, Dr. Tap said. There will be a Phase I portion of the trial to define the Phase II doses of the combination regimen.

The trial is unique because most new GIST clinical trials recruit patients that already have taken imatinib, sunitinib or other drugs and have already developed resistance to those drugs. This trial will try to show that treatment with a combination of imatinib and the MEK inhibitor from the start will be even more effective in combating GIST and will reduce the likelihood of secondary mutations that cause resistance.

Novartis Pharmaceuticals is co-developing the MEK inhibitor, MEK162, with Array Biopharma. MEK162 has been through Phase I trials and recently completed a Phase II trial in NRAS-mutant melanoma.

Dr. Tap said the research that opened the way to this new approach was led by his colleague at MSKCC, Dr. Ping Chi. She was able to show that ETV1, a transcription factor, was essential to the survival of GIST; while it was hard to target ETV1 because it didn’t have molecule-binding pockets that could be blocked by drugs, she found a way around this problem by discovering that MEK inhibitors could do that job.

“MEK inhibitors alone doesn’t seem to be great, but by doing combination therapy with imatinib we get a dramatic response,” Dr. Chi said. ETV1 is a master regulator that is highly expressed in all GISTS.

“Ping’s discovery is one of the major discoveries that we have seen in GIST research since the discovery of KIT,” Dr. Tap said.


ETV1 inhibitor takes lead in combination approach to clinical trials
Posted by Phil Avila – May 20, 2013 – News, Research
In 2010, Dr. Chi published a study she led, “ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours,” in Nature.

10. May 2013 · Comments Off · Categories: Video

 

Annual GCRF Meetng OHSU

      

 

 

 

 

 
01. January 2013 · Comments Off · Categories: Donate, In Memory · Tags: ,

GCRF would like to thank JULIE CRAMER for spearheading another wonderful event.  Held on Feb 23rd  at the Merion, in Cinnaminson, NJ.  This annual event raises money to help eradicate GIST.  Julie began the event to honor the memory of her dad, Mark Becker.

We at GCRF want to thank Julie for a great job well done.  Enjoy the following video, to get a taste of what the evening held…

Watch Video of the Event…



22. November 2012 · Comments Off · Categories: Donate, Event Calendar · Tags:

More videos available, click link below…

More »

11. September 2012 · Comments Off · Categories: Donate, Event Calendar · Tags:

2012 Peter Thomas 

Ride For A Cure
Cycling 1,000 Miles in 10 Days
Cape Town, South Africa

Ride for the Cure
 

The GIST Cancer Research Fund’s Cycling Warriors took to the road on October 23, 2012 for their 1,000-mile, 10-day crusade in the fight against GIST Cancer.

The spirit of Peter Thomas led the way and along with Riette and Dylan Thomas (and Wayne Thomas in tow), the riders began and ended a triumphant journey along the rugged South Africa coast.

 

It all started in Gordon’s Bay and concluded in Cape Town. It was the toughest and most challenging of the three Peter Thomas Memorial Rides For A Cure. It stretched the riders physically, mentally and emotionally. They crossed fourteen mountain passes and endured gale force headwinds that were so strong that it almost blew the riders off their bikes.

 

While each cyclist came for a different reason on this trip, the camaraderie and banter amongst the group was certainly a unique experience for many. You do have to ask yourself the question, why some come back to do this grueling ride every three years? Through all the adversity, this fantastic group of GIST Cyclists left their jobs, families and comforts of home to cycle 1,000 miles in 10 days to raise money for the GIST More »

04. September 2012 · Comments Off · Categories: Grants and Research, News · Tags:

University of Pittsburgh

PITTSBURGH, Aug. 23, 2012 – For the seventh year in a row, researchers from the University of Pittsburgh Cancer Institute (UPCI), partner with UPMC CancerCenter, have received funding from the GIST Cancer Research Fund – a patient-driven organization that funds research on gastrointestinal stromal tumors (GISTs). These tumors occur in the gastrointestinal tract and initially can be successfully treated with the targeted therapy drug Gleevec, but rapidly develop resistance to the treatment.

The $120,000 award supports the research of Anette Duensing, M.D., assistant professor of pathology, University of Pittsburgh School of Medicine. According to Dr. Duensing, GIST research in her laboratory aims to better understand the biology of More »

The GCRF has made available the various updates and technical presentations from recently held sponsored events.  These include:


Gist and Sarcoma Cancer Research Conference—May 2, 2012 (Brigham & Women's Hospital)

 


Gist Cancer Research Conference—April 4, 2012 (Memorial Sloan-Kettering Cancer Center)

22. May 2012 · Comments Off · Categories: Donate · Tags: ,

The Gist Cancer Research Fund once again in 2012 donated 100% of funds raised to institutions working for a cure to GIST.  Below are some of the highlights from this year's grant presentations.

Photos from 2012 Grant Presentation at University of Pittsburgh

GIST Research Update Presentation at 2012 Pittsburgh event.

Photos from the 2012 Presentation at University of Oregon

Presentation from the University of Oregon Meeting

Photos from the 2012 Presentation at Fox Chase Cancer Center

The War on GIST: Life, Death, and Everything In Between - GCRF Research Update 2012 (Michael Heinrich, M.D.)

GIST Research Updates: May 2012, Heinrich & Corless Laboratories

GIST Research Update:  Fox Chase Cancer Center (Margaret von Mehren, MD)

Oncogenesis of wild type GIST: some clarity from genetics (Fox Chase Cancer Center - Martin G. Belinsky Ph.D. )

Evaluating new therapies in GIST using in vivo molecular imaging (Fox Chase Cancer Center - Lori Rink, Ph.D.)